Small molecule · Activator of phenylalanine hydroxylase (PAH) · developed by Biomarin Pharm
Sapropterin is a synthetic form of tetrahydrobiopterin (BH4), the cofactor of phenylalanine hydroxylase (PAH). It activates residual PAH enzyme activity to improve the oxidative metabolism of phenylalanine. It is studied in GTP cyclohydrolase deficiency and in heart failure and cardiovascular disease.
Summary written with AI from the sources listed at the end of this page.
From the indications section of the FDA label (version of Aug 26, 2024). Read the full label for the exact wording, limitations and safety information.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01425528 | Phase 1/2 | GTP Cyclohydrolase Deficiency | Completed | BMRN |
| NCT02353312 | N/A | Heart Failure | Completed | BMRN |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cardiovascular DiseaseGTP Cyclohydrolase DeficiencyHeart Failure
Updated Nov 8, 2026. Something wrong or missing? Report it on the BMRN page.
See BMRN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
BMRN catalysts and pipeline →